Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 33 publications
Phase 2/3, Open-label, Randomized, Active-controlled Clinical Trial Evaluating the Safety and Efficacy of Imipenem/Cilastatin/Relebactam in Pediatric Patients From Birth to Less Than 18 Years With Gram-negative Bacterial Infections.
Journal: The Pediatric infectious disease journal
Published: July 04, 2026
Imipenem/cilastatin/relebactam dosing regimen justification using exposure-efficacy analyses in participants with hospital-acquired bacterial pneumonia or ventilator-associated bacterial pneumonia in the RESTORE-IMI 2 phase 3 study.
Journal: Antimicrobial agents and chemotherapy
Published: January 26, 2026
Erratum to "Impact of baseline humoral immunity on treatment outcomes with molnupiravir in the MOVe-OUT randomized, controlled trial" [Virology 613 (2026) 110710].
Journal: Virology
Published: November 27, 2025
Impact of differences between interim and post-interim analysis populations on outcomes of a group sequential trial: Example of the MOVe-OUT study.
Journal: Clinical trials (London, England)
Published: March 03, 2025
Comparison of Molnupiravir Exposure-Response Relationships for Virology Response and Mechanism of Action Biomarkers With Clinical Outcomes in Treatment of COVID-19.
Journal: Clinical and translational science
Published: January 16, 2025
Correction to: Virologic Outcomes with Molnupiravir in Nonhospitalized Adult Patients with COVID-19 from the Randomized, Placebo-Controlled MOVe-OUT Trial.
Journal: Infectious diseases and therapy
Published: April 25, 2024
Respiratory virus coinfections during the COVID-19 pandemic: epidemiologic analysis and clinical outcomes from the Phase 2/3 molnupiravir trial (MOVe-OUT).
Journal: Microbiology spectrum
Published: February 01, 2024
Virologic Outcomes with Molnupiravir in Non-hospitalized Adult Patients with COVID-19 from the Randomized, Placebo-Controlled MOVe-OUT Trial.
Journal: Infectious diseases and therapy
Published: August 11, 2023
Molnupiravir for intra-household prevention of COVID-19: The MOVe-AHEAD randomized, placebo-controlled trial.
Journal: The Journal of infection
Published: May 23, 2023
Pharmacokinetics, Safety, and Tolerability of Imipenem/Cilastatin/Relebactam in Children with Confirmed or Suspected Gram-Negative Bacterial Infections: A Phase 1b, Open-Label, Single-Dose Clinical Trial.
Journal: Journal of clinical pharmacology
Published: April 18, 2023
Impact of Molnupiravir Treatment on Patient-Reported COVID-19 Symptoms in the Phase 3 MOVe-OUT Trial: A Randomized, Placebo-Controlled Trial.
Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Published: March 23, 2023
Last Updated: 09/26/2026